心血管病患者使用依洛尤单抗注射液的经济性评价

Economic Evaluation of the Use of Evolocumab in Patients with Cardiovascular Disease

摘要: 目的：系统评价心血管病患者使用依洛尤单抗注射液的经济性情况。方法：运用计算机检索数据库，包括中国知网、万方、维普、PubMed、Embase、Cochrane Library、Web of Science等。检索患者使用依洛尤单抗注射液后的经济学评价，检索时限为2015年至2025年2月30日。筛选文献，对纳入的研究进行资料提取分析，观察依洛尤单抗注射液使用的经济性情况。结果：共纳入23项研究，有9个具有经济性，12个研究不具有经济性，有2个研究提示在疾病严重程度不同的时候经济性不同。在中国，依洛尤单抗注射液统一降价为283.5元/支，依洛尤单抗注射液在各类患者的治疗中均具有经济性。结论：在中国，依洛尤单抗注射液在心血管病治疗中具有经济性。

Abstract: Objective: To systematically evaluate the economic benefits of using Evolocumab in patients with cardiovascular disease. Methods: Computer searches were conducted on databases such as China National Knowledge Infrastructure (CNKI), Wanfang, VIP, PubMed, Embase, Cochrane Library, and Web of Science. The search period was from 2015 to February 30, 2025, focusing on the economic evaluations of patients using Evolocumab. Literature was screened, and data from the included studies were extracted and analyzed to assess the economic benefits of Evolocumab. Results: A total of 23 studies were included, with 9 showing economic benefits, 12 not, and 2 indicating varying economic benefits depending on the severity of the disease. In China, Evolocumab injection has been uniformly reduced to 283.5 yuan per vial, and it is economically beneficial for treating various patient groups. Conclusion: Evolocumab is cost-effective in the treatment of cardiovascular disease in China.